Thrivent Financial For Lutherans Uni Qure N.V. Transaction History

Thrivent Financial For Lutherans

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $473,356 - $945,009	42,568 Added 104.26%	83,395 $955,000
Q1 2023 May 17, 2023	SELL	$18.7 - $23.07 $26,759 - $33,013	-1,431 Reduced 3.39%	40,827 $822,000
Q4 2022 Feb 08, 2023	SELL	$18.12 - $27.32 $4,530 - $6,830	-250 Reduced 0.59%	42,258 $958,000
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $114,801 - $172,675	6,761 Added 18.91%	42,508 $797,000
Q2 2022 Aug 16, 2022	SELL	$13.15 - $20.45 $335,351 - $521,515	-25,502 Reduced 41.64%	35,747 $666,000
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $247 - $365	17 Added 0.03%	61,249 $1.11 Million
Q4 2021 Feb 16, 2022	BUY	$20.24 - $36.01 $651,404 - $1.16 Million	32,184 Added 110.8%	61,232 $1.27 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $755,538 - $1.11 Million	29,048 New	29,048 $930,000
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $301,005 - $431,455	-8,515 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$35.98 - $47.66 $306,369 - $405,824	8,515 New	8,515 $314,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.